151 related articles for article (PubMed ID: 33860650)
1. Circulating pro-gastrin releasing peptide (ProGRP) in patients with medullary thyroid carcinoma.
Giovanella L; Fontana M; Keller F; Campenni' A; Ceriani L; Paone G
Clin Chem Lab Med; 2021 Aug; 59(9):1569-1573. PubMed ID: 33860650
[TBL] [Abstract][Full Text] [Related]
2. Utility of proGRP as a tumor marker in the medullary thyroid carcinoma.
Parra-Robert M; Orois A; Augé JM; Halperin I; Filella X; Molina R
Clin Chem Lab Med; 2017 Mar; 55(3):441-446. PubMed ID: 27754959
[TBL] [Abstract][Full Text] [Related]
3. Exploring the application value of pro-gastrin-releasing peptide in the clinical diagnosis and surgical treatment of medullary thyroid carcinoma.
Miao Q; Lv X; Luo L; Zhang J; Cai B
Cancer Med; 2023 Oct; 12(19):19576-19582. PubMed ID: 37754747
[TBL] [Abstract][Full Text] [Related]
4. ProGRP AS A NOVEL BIOMARKER FOR THE DIFFERENTIAL DIAGNOSIS OF MEDULLARY THYROID CARCINOMA IN PATIENTS WITH THYROID NODULES.
Liang X; Zhu J; Cai M; Dai Z; Fang L; Chen H; Yu L; Lin Y; Lin E; Wu G
Endocr Pract; 2020 May; 26(5):514-522. PubMed ID: 32045291
[No Abstract] [Full Text] [Related]
5. Demonstration and diagnostic significance of pro-gastrin-releasing peptide in medullary thyroid carcinoma.
Inaji H; Komoike Y; Motomura K; Higashiyama M; Ohtsuru M; Funai H; Kasugai T; Koyama H
Oncology; 2000 Aug; 59(2):122-5. PubMed ID: 10971170
[TBL] [Abstract][Full Text] [Related]
6. Clinical performance of calcitonin and procalcitonin Elecsys
Giovanella L; Fontana M; Keller F; Verburg FA; Ceriani L
Clin Chem Lab Med; 2021 Mar; 59(4):743-747. PubMed ID: 33085633
[TBL] [Abstract][Full Text] [Related]
7. Utilizing the circulating tumor markers in diagnosis and management of medullary thyroid cancer.
Zarkesh M; Arab N; Tavangar SM; Nozhat Z; Fanaei SM; Hedayati M
Pathol Res Pract; 2022 Jan; 229():153694. PubMed ID: 34929598
[TBL] [Abstract][Full Text] [Related]
8. [Application of serum markers in medullary thyroid carcinoma].
Han XD; Lu RQ; Hu HY; Guo L
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Dec; 55(12):1468-1474. PubMed ID: 34963245
[No Abstract] [Full Text] [Related]
9. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
[TBL] [Abstract][Full Text] [Related]
10. Combining serum calcitonin, carcinoembryonic antigen, and neuron-specific enolase to predict lateral lymph node metastasis in medullary thyroid carcinoma.
Ye L; Zhou X; Lu J; Wang Y; Xie X; Zhang J
J Clin Lab Anal; 2020 Jul; 34(7):e23278. PubMed ID: 32141647
[TBL] [Abstract][Full Text] [Related]
11. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
[TBL] [Abstract][Full Text] [Related]
12. High CEA levels in a case of resected colorectal cancer: delayed diagnosis of metachronous medullary thyroid cancer.
Chen SW; Chen YK
World J Surg Oncol; 2017 Dec; 15(1):230. PubMed ID: 29284496
[TBL] [Abstract][Full Text] [Related]
13. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?
Behr TM; Gratz S; Markus PM; Dunn RM; Hüfner M; Schauer A; Fischer M; Munz DL; Becker H; Becker W
Cancer; 1997 Dec; 80(12 Suppl):2436-57. PubMed ID: 9406695
[TBL] [Abstract][Full Text] [Related]
14. Serum calcitonin negative medullary thyroid carcinoma: a systematic review of the literature.
Trimboli P; Giovanella L
Clin Chem Lab Med; 2015 Sep; 53(10):1507-14. PubMed ID: 25781697
[TBL] [Abstract][Full Text] [Related]
15. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
16. A Review of the Significance in Measuring Preoperative and Postoperative Carcinoembryonic Antigen (CEA) Values in Patients with Medullary Thyroid Carcinoma (MTC).
Passos I; Stefanidou E; Meditskou-Eythymiadou S; Mironidou-Tzouveleki M; Manaki V; Magra V; Laskou S; Mantalovas S; Pantea S; Kesisoglou I; Sapalidis K
Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34208296
[No Abstract] [Full Text] [Related]
17. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
Yashi M; Muraishi O; Kobayashi Y; Tokue A; Nanjo H
Prostate; 2002 May; 51(2):84-97. PubMed ID: 11948963
[TBL] [Abstract][Full Text] [Related]
18. Increased Progastrin-Releasing Peptide Expression is Associated with Progression in Gastric Cancer Patients.
Li L; Yin X; Meng H; Hu J; Yu Z; Xu J
Yonsei Med J; 2020 Jan; 61(1):15-19. PubMed ID: 31887795
[TBL] [Abstract][Full Text] [Related]
19. Carcinoembryonic antigen levels correlated with advanced disease in medullary thyroid cancer.
Turkdogan S; Forest VI; Hier MP; Tamilia M; Florea A; Payne RJ
J Otolaryngol Head Neck Surg; 2018 Sep; 47(1):55. PubMed ID: 30223887
[TBL] [Abstract][Full Text] [Related]
20. [Medullary thyroid carcinoma].
Tiedje V; Ting S; Dralle H; Schmid KW; Führer D
Internist (Berl); 2015 Sep; 56(9):1019-31. PubMed ID: 26338063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
